Open discussion

Clinical Cancer Research

Volumn 13, Issue 2 II, 2007, Pages

  Figlin, ^a   Sosman, ^a   Flaherty, ^a   Rini, ^a   Atkins, ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; BIOLOGICAL MARKER; ERLOTINIB; SORAFENIB; ANGIOGENESIS INHIBITOR; ANSAMYCIN DERIVATIVE; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; EVEROLIMUS; FIBROBLAST GROWTH FACTOR; HYPOXIA INDUCIBLE FACTOR 1ALPHA; HYPOXIA INDUCIBLE FACTOR 2ALPHA; IMATINIB; INTERFERON; INTERLEUKIN 2; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; PLACEBO; PLATELET DERIVED GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; PROTEIN TYROSINE KINASE INHIBITOR; PYRIDOXINE; RAF PROTEIN; SUNITINIB; TEMSIROLIMUS; VASCULOTROPIN; VASCULOTROPIN RECEPTOR; VASCULOTROPIN RECEPTOR 2; VON HIPPEL LINDAU PROTEIN;

AREA UNDER THE CURVE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG POTENTIATION; DRUG SAFETY; HUMAN; KIDNEY CARCINOMA; MONOTHERAPY; NOTE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; ADVANCED CANCER; ANOREXIA; CANCER GROWTH; COMBINATION CHEMOTHERAPY; CONFERENCE PAPER; DRUG APPROVAL; DRUG MECHANISM; DRUG MEGADOSE; DRUG TOLERABILITY; GENE EXPRESSION; GENE LOSS; HAND FOOT SYNDROME; MULTIPLE CYCLE TREATMENT; PROGNOSIS; PROPHYLAXIS; SIGNAL TRANSDUCTION; STOMATITIS; TREATMENT PLANNING; TREATMENT RESPONSE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, RENAL CELL; CLINICAL TRIALS; DISEASE-FREE SURVIVAL; HUMANS; INTERLEUKIN-2; KIDNEY NEOPLASMS; MODELS, BIOLOGICAL; RESEARCH DESIGN; SIGNAL TRANSDUCTION;

EID: 33846878944     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-06-1975     Document Type: Note

References (23)

1. Hotte SJ, Hirte HW. BAY 43-9006: early clinical data in patients with advanced solid malignancies. Curr Pharm Des 2002;8:2249-53.
2. Kaelin WG, Jr. The von Hippel-Lindau gene, kidney cancer, and oxygen sensing. J Am Soc Nephrol 2003;14:2703-11.
3. Motzer RJ, Hoosen S, Bello CL, Christensen JG. Sunitinib malate for the treatment of solid tumours: a review of current clinical data. Expert Opin Investig Drugs 2006;15:553-61.
4. Molecule of the month. Sorafenib. Drug News Perspect 2006;19:119.
5. Ferrara N. VEGF as a therapeutic target in cancer. Oncology 2005;69:11-6.
6. Holash J, Davis S, Papadopoulos N, et al. VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc Natl Acad Sci U S A 2002;99:11393-8.
7. Atkins M, Jones CA, Kirkpatrick P. Sunitinib maleate. Nat Rev Drug Discov 2006;5:279-80.
8. Arora A, Scholar EM. Role of tyrosine kinase inhibitors in cancer therapy. J Pharmacol Exp Ther 2005;315:971-9.
9. Veronese ML, O'Dwyer PJ. Monoclonal antibodies in the treatment of colorectal cancer. Eur J Cancer 2004;40:1292-301.
10. Yang JC, Haworth L, Sherry RM, et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003;349:427-34.
11. Patel PH, Chaganti RS, Motzer RJ. Targeted therapy for metastatic renal cell carcinoma. Br J Cancer 2006;94:614-9.
12. Ivan M, Kondo K, Yang H, et al. HIFα targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing. Science 2001;292:464-8.
13. Xu L, Eiseman JL, Egorin MJ, D'Argenio DZ. Physiologically based pharmacokinetics and molecular pharmacodynamics of 17-(allylamino)-17-demethoxy- geldanamycin and its active metabolite in tumor-bearing mice. J Pharmacokinet Pharmacodyn 2003;30:185-219.
14. Gollob JA. Sorafenib: scientific rationales for single-agent and combination therapy in clear-cell renal cell carcinoma [see comment]. Clin Genitourin Cancer 2005;4:167-74.
15. Mukhopadhyay D, Knebelmann B, Cohen HT, Ananth S, Sukhatme VP. The von Hippel-Lindau tumor suppressor gene product interacts with Sp1 to repress vascular endothelial growth factor promoter activity. Mol Cell Biol 1997;17:5629-39.
16. Gemmill RM, Zhou M, Costa L, Korch C, Bukowski RM, Drabkin HA. Synergistic growth inhibition by Iressa and rapamycin is modulated by VHL mutations in renal cell carcinoma. Br J Cancer 2005;92:2266-77.
17. Hainsworth JD, Sosman JA, Spigel DR, Edwards DL, Baughman C, Greco A. Treatment of metastatic renal cell carcinoma with a combination of bevacizumab and erlotinib. J Clin Oncol 2005;23:7889-96.
18. Casanovas O, Hicklin DJ, Bergers G, Hanahan D. Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell 2005;8:299-309.
19. Datta K, Nambudripad R, Pal S, Zhou M, Cohen HT, Mukhopadhyay D. Inhibition of insulin-like growth factor-I-mediated cell signaling by the von Hippel-Lindau gene product in renal cancer. J Biol Chem 2000;275:20700-6.
20. Dutcher J. Current status of interleukin-2 therapy for metastatic renal cell carcinoma and metastatic melanoma. Oncology (Huntington) 2002;16:4-10.
21. Gabrilovich DI, Nadaf S, Corak J, Berzofsky JA, Carbone DP. Dendritic cells in anti-tumor immune responses. II. Dendritic cells grown from bone marrow precursors, but not mature DC from tumor-bearing mice are effective antigen carriers in the therapy of established tumors. Cell Immunol 1996;170:111-20.
22. Almand B, Clark JI, Nikitina E, et al. Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer. J Immunol 2001;166:678-89.
23. Gabrilovich DI, Ishida T, Oyama T, et al. Vascular endothelial growth factor inhibits the development of dendritic cells and dramatically affects the differentiation of multiple hematopoietic lineages in vivo. Blood 1998;92:4150-66.